Most significantly, WntSI effectively overcame acquired resistance to EGFR‐TKIs resulting from MET amplification in both cell line‐derived and patient‐derived tumor xenograft mouse models, while exhibiting exceptional safety measures. This evidence concerns the gene EGFR and neoplasm.